^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ELTD1 (Adhesion G Protein-Coupled Receptor L4)

    i
    Other names: ELTD1, Adhesion G Protein-Coupled Receptor L4, EGF, Latrophilin And Seven Transmembrane Domain-Containing Protein 1, EGF, Latrophilin And Seven Transmembrane Domain Containing 1, EGF-TM7-Latrophilin-Related Protein, Lnc-ADGRL4-2, ETL Protein, KPG_003
    13d
    aGPCR-HEK: A Stable High-Expression Inducible Mammalian Cell Expression System for Adhesion GPCR Structural Biology Applications. (PubMed, Bio Protoc)
    • Uses flow cytometry enrichment of leaky GFP-positive cells to enhance inducibility and yield. • Provides suspension culture adaptation and large-scale tetracycline induction for structural biology-grade protein production suitable for purification and cryo-EM analysis.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    13d
    Purification of the Active-State G Protein-Coupled Receptor ADGRL4 for Cryo-Electron Microscopy Using a Modular Tag System and a Tethered mini-Gq. (PubMed, Bio Protoc)
    • Tethered mini-Gq increases stability and receptor cell-surface expression. • Modular purification tagging configuration provides freedom to change purification methodologies without having to perform additional receptor engineering or cloning.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    29d
    Stress-Induced ADGRL4 Orchestrates Tumor Progression and Metastasis by Inhibiting YAP1 Signaling and Activating Angiogenesis. (PubMed, Cancer Res)
    Notably, while restraining tumor growth by compromising proliferative activity, stress-induced ADGRL4 simultaneously diminished chemosensitivity and promoted angiogenesis, thereby heightening relapse risk. Thus, ADGRL4 emerges as a stress sensor that integrates YAP1 signaling with tumor angiogenesis to govern the balance between tumor-suppressing and tumor-promoting states, providing mechanistic insight into therapy-induced tumor progression.
    Journal
    |
    YAP1 (Yes associated protein 1) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • ATF2 (Activating Transcription Factor 2)
    2ms
    Tanshinone IIA&Icaritin -MPs regulated vascular normalization and restored tumor-infiltrating T lymphocyte function to boost anti-PD-1 therapy in melanoma lung metastasis. (PubMed, J Nanobiotechnology)
    Combining TSA&ICT-MP with α-PD-1 achieved a 70.33% suppression rate of lung metastasis and prolonged survival in murine models. This approach offers a promising strategy to enhance the efficacy of melanoma immunotherapy.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    icaritin (SNG-162)
    3ms
    Structure of the Gq-coupled adhesion receptor ADGRL4. (PubMed, Nat Commun)
    The overall fold of ADGRL4 is similar to that of other aGPCRs, but the coupling to Gq is distinct with fewer interactions between the receptor and G protein. The structure is consistent with ADGRL4 being activated by its tethered agonist and represents an important step towards the development of potential inhibitors for the treatment of multiple tumour types.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    over1year
    Comprehensive analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics revealed IER3 for predicting malignant progression and immunotherapy efficacy in glioma. (PubMed, Cancer Cell Int)
    In this study, we identified IER3 upregulation as an essential biomarker that could assist in adjuvant therapy and prognosis prediction for gliomas.
    Journal • IO biomarker
    |
    CCL2 (Chemokine (C-C motif) ligand 2) • PDGFA (Platelet Derived Growth Factor Subunit A) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • TGFBI (Transforming Growth Factor Beta Induced)
    |
    BRAF mutation
    |
    Tafinlar (dabrafenib)
    over1year
    Elucidating the role of tumor-associated ALOX5+ mast cells with transformative function in cervical cancer progression via single-cell RNA sequencing. (PubMed, Front Immunol)
    The prognostic model constructed based on the C2 ALOX5+MCs subset demonstrated excellent predictive value. These findings offer a fresh perspective for clinical decision-making in CC.
    Journal
    |
    CALR (Calreticulin) • IL32 (Interleukin 32) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    over1year
    Apoptotic effect of melatonin on ER-positive breast cancer cell lines: ADGRL4 gene expression and promoter methylation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    We found that melatonin has anti-cancer effects on BC cells. In addition, ADGRL4 expression can potentially be used as a prognostic biomarker in BC.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    over1year
    Histopathological growth pattern and vessel co-option in intrahepatic cholangiocarcinoma. (PubMed, Med Mol Morphol)
    iCCA (sub)types and HGPs were closely related to vessel co-option and immune-related factors (lymphatic vessels, lymphocytes, and neutrophils). In conclusion, HGPs and vascular mechanisms characterize iCCA (sub)types and vessel co-option linked to the immune microenvironment.
    Journal
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    almost2years
    ELTD1 Review: New Regulator of Angiogenesis in Glioma. (PubMed, Curr Health Sci J)
    This review aimed to translate these insights into effective clinical treatments. However, several gaps remain in our knowledge regarding ELTD1 ligands and their potential involvement in other physiological or pathological processes that future research can address to elucidate the role of ELTD1 in cancer, through angiogenesis and other intracellular pathways.
    Review • Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    2years
    Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations. (PubMed, Clin Cancer Res)
    Our results illustrate that evolution of MF from ET/PV/PrePMF likely advances with age, accumulation of mutations, and activation of proliferative pathways. The genes and pathways identified by integrated genomics approach provide insight into disease transformation and progression, and potential targets for therapeutic intervention.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • DNASE1L3 (Deoxyribonuclease 1 Like 3)
    |
    KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation